These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis. Praharaj DL, Anand AC. J Clin Exp Hepatol; 2022; 12(2):575-594. PubMed ID: 35535075 [Abstract] [Full Text] [Related]
25. The management of hepatorenal syndrome. Carl DE, Sanyal A. Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378 [Abstract] [Full Text] [Related]
26. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Wong F, Pantea L, Sniderman K. Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086 [Abstract] [Full Text] [Related]
28. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Rössle M, Gerbes AL. Gut; 2010 Jul; 59(7):988-1000. PubMed ID: 20581246 [Abstract] [Full Text] [Related]
29. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T. Gut; 2000 Aug; 47(2):288-95. PubMed ID: 10896924 [Abstract] [Full Text] [Related]
30. Hepatorenal syndrome: a review. Testino G, Ferro C. Hepatogastroenterology; 2010 Aug; 57(102-103):1279-84. PubMed ID: 21410072 [Abstract] [Full Text] [Related]
31. The natural history and management of hepatorenal disorders: from pre-ascites to hepatorenal syndrome. Blendis L, Wong F. Clin Med (Lond); 2003 Aug; 3(2):154-9. PubMed ID: 12737373 [Abstract] [Full Text] [Related]
32. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival? Gülberg V, Gerbes AL. Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953 [Abstract] [Full Text] [Related]
34. Recent advances in our understanding of hepatorenal syndrome. Wong F. Nat Rev Gastroenterol Hepatol; 2012 May 22; 9(7):382-91. PubMed ID: 22614754 [Abstract] [Full Text] [Related]
35. Diagnosis and therapy of ascites in liver cirrhosis. Biecker E. World J Gastroenterol; 2011 Mar 14; 17(10):1237-48. PubMed ID: 21455322 [Abstract] [Full Text] [Related]
37. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome. Senzolo M, Cholongitas E, Tibballs J, Burroughs A, Patch D. Eur J Gastroenterol Hepatol; 2006 Nov 27; 18(11):1143-50. PubMed ID: 17033432 [Abstract] [Full Text] [Related]
38. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J. Gastroenterology; 2002 Dec 27; 123(6):1839-47. PubMed ID: 12454841 [Abstract] [Full Text] [Related]
39. Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. Tan HK, James PD, Wong F. Dig Dis Sci; 2016 Oct 27; 61(10):3084-3092. PubMed ID: 27048451 [Abstract] [Full Text] [Related]